Skip to main content

Topic

Biosimilars

856 published works

  1. Biosimilars Law Bulletin

    PTAB Reforms Shift the Battleground: Why Ex Parte Reexaminations Are Gaining Ground as IPRs Fade

    By Jake Rosvold, Aydin H. Harston

    In the evolving biosimilar landscape, patent challenges remain a critical strategy to clear the path for market entry.  Recent reforms at the Patent Trial and Appeal Board (PTAB) under Director…

  2. Biosimilars Law Bulletin

    How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline – Updated January 22, 2026

    By Alex Shaver, Aydin H. Harston

    Many Prolia®/Xgeva® (denosumab) biosimilars approved in 2025 by FDA and EMA. FDA grants first interchangeable status for rapid acting insulin aspart, KristyTM. EMA sets record with 44 biosimilar authorizations in…

  3. Big Molecule Watch

    Year in Review: Top Legal Developments of 2025

    By Tara Thigpen|Riley Wyberg|Sam Herron

    This past year contained a number of significant developments in litigation involving biologics and biosimilars.  The following is a recap of the top three legal developments that we covered on…

  4. Spicy IP

    Biosimilarity is not Infringement- Full Stop

    By Yogesh Byadwal

    Translation: Don’t think we are on the same side, we are different. On Monday, a DB of the DHC allowed Zydus to manufacture and market a biosimilar of the drug Nivolumab, marketed…

  5. Big Molecule Watch

    Year in Review: Big Deals of 2025

    By Timothy Beavers|Yoko Bian

    As we head into what is anticipated to be a strong year for biopharma dealmaking, we look back at some of the biggest deals in 2025 that focus on biologics…

  6. Big Molecule Watch

    Celltrion and Sandoz Launch Their Aflibercept Biosimilars in Europe

    By Allegra Padula

    On November 27, 2025, Celltrion announced that Health Canada approved EYDENZELT® (aflibercept-boav), a biosimilar referencing Regeneron’s EYLEA® (aflibercept), in both vial and pre-filled syringe form, to treat all indications approved…

  7. Big Molecule Watch

    FDA Approves mAbxience and Amneal’s Denosumab Biosimilars

    By Riley Wyberg

    On December 22, 2025, the FDA approved mAbxience and Amneal’s Biologics Licensing Applications (BLAs) for BONCRESA (denosumab-mobz) and OZILTUS (denosumab-mobz), biosimilars referencing Amgen’s PROLIA® (denosumab) and XGEVA® (denosumab), respectively.  Under…

  8. Big Molecule Watch

    Biocon and Regeneron Enter Global Settlement on Aflibercept Biosimilar

    By Riley Wyberg

    On December 13, 2025, Biocon Biologics Ltd. (“Biocon”) and Regeneron Pharmaceuticals, Inc. (“Regeneron”) entered into a license and settlement agreement to dismiss all pending claims in the parties’ disputes over…

  9. Big Molecule Watch

    FDA Approves New Dose for Celltrion’s OMLYCLO (omalizumab-igec)

    By Jenevieve Nutovits

    On December 3, 2025, Celltrion announced that the FDA has approved a new dose of OMLYCLO (omalizumab-igec), the first and only biosimilar designated as interchangeable with Genentech and Novartis’s XOLAIR…

  10. Big Molecule Watch

    European Biosimilar Updates – Six Denosumab Launches and Positive Opinion for Samsung Bioepis’s BYOOVIZ

    By Timothy Beavers|Darlene Staines

    Just in December, six companies have announced the launch of their denosumab biosimilars in Europe: Sandoz, Samsung Bioepis, Fresenius Kabi, Zentiva, Biocon Biologics, and Accord. On December 1, 2025: Sandoz…